Study of CD10 immunohistochemical marker expression in prostate cancer and its association with some clinicopathologic markers

Document Type : Original Article


1 Department Pathology, Faculty of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Pathology, Faculty of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran.


Background: The present study was designed to evaluate the frequency of natural endopeptidase (NEP) or CD10 in prostate carcinoma cells in order to evaluate its association with tumor prognostic findings.
Materials and Methods: In this cross-sectional descriptive study, tissue samples of patients referred to Imam Khomeini, Shahid Baqaei and Golestan hospitals of Ahwaz with the diagnosis of prostate adenocarcinoma and benign prostatic hyperplasia were used. Clinical and demographic data of patients were extracted from hospital records.. Anti CD10 monoclonal antibody was used for immunohistochemical staining.
Results: In this study, 51 prostate samples (41 malignant and 10 benign) were studied. The mean age of the patients was 68.4 years, ranging from 40 to 92 years. Stage of cancer was organ confined in the majority of cases (75%). The pattern of expression, expression intensity and staining intensity in malignant specimens were significantly different than benign tissues. CD10 expression decreased in more than 50% of malignant cases. Also, the staining intensity of this marker was significantly lower in malignant samples. In addition, evaluation of correlation between staining intensity with other studied variables showed that there was a significant relationship between staining intensity and gleason score (p <0.0001).
Conclusion: Overall, the findings of the present study indicate that expression of the CD10 marker in malignant prostate tumors is decreased or abolished. However, this marker is expressed in advanced stages of the tumor and is related to the invasive pattern of the tumor.


1-Simforoush N, Nouralizadeh A, Soltani MH, Nafar M. Iranian Text book of urology. 2nd ed. Vol (2). Tehran: Teimourzadeh; 2013. p. 415-49.
2-Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A, et al. Cancer statistics for African Americans. CA Cancer J Clin. 2002;52(6):326-41.
3-Roshandel G, Ghanbari-Motlagh A, Partovipour E, Salavati F, Hasanpour-Heidari S, Mohammadi G, Khoshaabi M, Sadjadi A, Davanlou M, Tavangar SM, Abadi H. Cancer incidence in Iran in 2014: results of the Iranian National Population-based Cancer Registry. Cancer epidemiology. 2019 Aug 1;61:50-8.
4-Sadjadi A, Nooraie M, Ghorbani A, Alimohammadian M, Zahedi MJ, DarvishMoghadam S, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med. 2007;10(4):481-5.
5-Malekzadeh R. Incidences of differnet cancers in Iran. The 16th International Congress of Geographic. Medicine Shiraz University of Medical Sciences, Shiraz, Iran. 2003;1(4).
6-Hosseini M, Jahani Y, Mahmoodi M, Eshraghian MR, Yahyapour Y, Keshtkar AA. The assessment of risk factors for prostate cancer in Mazandaran province, Iran. J Gorgan Uni Med Sci. 2008;10(3):58-64.
7-Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985;45(8):3663-7.
8-O’Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol. 1990;417(3):191-6.
9-Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274(18):1445-9
10-Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell- specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26(9):1161-8.
11-Gaudin PB, Reuter VE. Benign mimics of prostatic adenocarcinoma on needle biopsy. Anat Pathol 1997;2:111-34.
12-Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V, Alavi M. Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Modern Pathology. 2013 Jun;26(6):849.
13-Saranya D. Analysis of Immunohistochemical Expression of CD10 in the Lesions of Prostate (Doctoral dissertation, Chengalpattu Medical College, Chengalpattu).
14-Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. The Prostate. 2003 Apr 1;55(1):71-80.
15-Saranya D. Analysis of immunohistochemical expression of CD10 in the malignant lesions of prostate. IOSR-J of Dental and Med Sci. 2017;16:78-82.
16-Era M, True L, Siegel A, Porter M, Sherertz T, Liu A. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urology. 2007;1471 -90.
17-Fleischmann A, Schlimm T, Huland H, Kollermann J, Simon P, Mirlacher M et al. Distinct subcellular expression patterns of neutral endopeptidase in prostate cancer predict diverging clinical courses in surgically treated patients. Clinical cancer research. 2008;14:7838- 42.
18-Kaur M, Gupta R, Pant L, Singh S. CD10 expression pattern in prostatic adenocarcinoma: Elucidation of differences between Gleason's grades. The Malaysian journal of pathology. 2018 Apr 1;40(1):57-60.